Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive-Dose Durvalumab and Radiation in Stage III NSCLC
NCT04372927Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University of Washington. Started Dec 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04372927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372927.